Saturday, 31 October 2026European Markets

Parrot Soars Over 21% In One Day - Investors Take Flight!

Loading stream...

(vianews) - investors are piling into parrot (cac 40: parro.pa), leading it to gain 21.66% and increase by eur2.64 as of 15:25 est today despite two sessions of declining stocks. meanwhile, cac 40 index is up 0.27% to eur7,589.04 as parrot closed with eur2.17 last night (61.25% below its 52-week high of eur5.60).

about parrot

parrot s.a. specializes in offering professional drones, software, and services around the world. their product offering includes open flight, air sdk, ground sdk, sphinx and c.a.d modeling as well as python controller programming pdraw; these can be tailored specifically for industries like inspection, emergency response, firefighting search & rescue security surveying etc. since 1994 they are headquartered out of paris france.

yearly analysis

given this information, parrot's stock is currently trading at eur2.64, significantly below its 52-week high of eur5.60 but higher than its 52-week low of eur2.10. parrot's sales growth is projected to decline significantly this year by 26.3%; however, they anticipate some improvement next year with 4.5% projected as their forecasted increase. given this information, investors should exercise caution before investing in parrot stock as its negative sales growth this year may indicate underlying problems with company performance. furthermore, its current trading price is lower than its 52-week high which may indicate negative investor sentiment towards it's future performance; however anticipated growth next year may provide hope of recovery; overall investors should conduct extensive research before making investment decisions regarding parrot shares.

technical analysis

parrot's stock has experienced a downward trend recently, currently sitting above its 50-day moving average of eur2.41 yet well below its 200-day moving average of eur3.46. nonetheless, trading volume increased significantly; today's total of 58,867 being 7777.04% higher than its usual total of 6,712, suggesting investors are paying closer attention to parrot. for the last week, month and quarter, volatility of this stock has been negative with average intraday variations ranging between -1.18%, -0.60% and 3.11%; with an amplitude of average volatility reaching up to 3.54% for every one week of volatility (3.54% in one week, 2.03% in one month and 3.11% over three quarters). according to the stochastic oscillator, parrot stock appears oversold (=20), signaling potential price rebound. investors should keep in mind that this indicator alone should not be enough to make investment decisions about this stock; other considerations must also be taken into account, including company financial performance and market conditions before making their final choice.

quarter analysis

based on the available data, parrot's sales growth for both current and subsequent quarters is negative 26.3% - suggesting a decline in sales when compared with prior periods. although year-on-year quarterly revenue growth over the past 12 months increased by 3.3%, current negative sales growth suggests that it may be facing challenges when expanding revenue growth and investors should exercise caution before considering investing in parrot. investors should keep other factors such as changes in market conditions, new product releases or management decisions into consideration as these could impact its performance too - particularly as these could affect its performance when making investment decisions relating to its performance such as changing market conditions or product launches or management decisions potentially altering growth potential over time.

equity analysis

parrot's trailing twelve months eps stands at eur-0.91, indicating negative earnings per share and suggesting it may not be producing enough profits to maintain operations or deliver returns to shareholders. parrot's return on equity (roe) for the twelve trailing months stands at negative -37.52%. a negative roe indicates that the company may not be providing sufficient returns on the funds invested by shareholders - an indication of possible investors concerns regarding performance of equity investments by parrot. due to these financial metrics, investors may wish to exercise caution when considering an investment in parrot. care should be taken when reviewing its financial statements, management team and growth prospects in order to ascertain potential for profitability and returns in the future.

more news about parrot (parro.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com